NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.moleculin.comThe clinical trial for WP1066 in combination with radiation therapy, targeting newly diagnosed glioblastoma patients, is expected to conclude on December 27, 2028. The study, sponsored by Northwestern University, aims to determine the efficacy of WP1066 in improving progression-free survival outcomes and safety metrics. It is currently recruiting participants with glioblastoma, and the trial will also assess systemic immunological responses and changes in tumor microenvironment. The results may be significant in evaluating treatment options for this aggressive cancer type, which historically has limited therapeutic success. The expected completion date will be closely monitored by investors for potential future indications regarding the drug's performance in later stages of clinical development.
clinical trial completionMoleculin Biotech, Inc. expects to complete a clinical trial by August 1, 2030, evaluating L-Annamycin for Injection in combination with Cytarabine Injection as a second-line therapy for adult patients with refractory/relapsed acute myeloid leukemia (AML). The trial is currently in a pivotal phase 2/3 design and aims to determine the optimal dosage of L-Annamycin through two parts. Part A involves assessing the efficacy and safety of two dosage levels compared to placebo, while Part B will focus on confirming the optimal regimen in a larger patient population. The study, which has an estimated enrollment of 334 participants, reflects ongoing efforts to improve treatment outcomes in this challenging patient demographic.
Clinical Trial Completion